SCHEMBL825819

SCHEMBL825819

CC(C)(C)n1ncc(C(=O)O)c1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NR4A3 Q92570 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
LDHA P00338 1/20 0.40
KDM4C Q9H3R0 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
DHODH Q02127 1/20 0.38
MAP2K1 Q02750 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493215 0.86 KDM4E (0.50) ALDH1A1AURKAAURKBSMN1; SMN2KDM4C
SCHEMBL15750693 0.84 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2POLBMAPTKDM4C
SCHEMBL951340 0.81 ALDH1A1 (0.41) ALDH1A1AURKAAURKBSMN1; SMN2NR4A3
SCHEMBL23403250 0.78 HTR2A (0.40) ALDH1A1AURKAAURKBSMN1; SMN2POLB
SCHEMBL826906 0.78 ROCK1 (0.49) ALDH1A1NR4A3LDHADHODHKDM4E
SCHEMBL2329024 0.78 ALDH1A1 (0.41) ALDH1A1AURKAAURKBSMN1; SMN2POLB
SCHEMBL2329029 0.75 ALDH1A1 (0.44) ALDH1A1AURKAAURKBSMN1; SMN2MAPT
SCHEMBL5066520 0.74 KDM4E (0.43) ALDH1A1SMN1; SMN2NR4A3POLBMAPT
SCHEMBL574333 0.74 KDM4E (0.44) ALDH1A1SMN1; SMN2NR4A3POLBMAPT
SCHEMBL4497271 0.73 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2NR4A3POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358689-B9 BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS TAKEDA PHARMACEUTICAL (JP) 2016-08-03 EP disclosed
EP-2358689-B1 BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS TAKEDA PHARMACEUTICAL (JP) 2015-09-30 EP disclosed
US-8497274-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-30 US disclosed
US-20120214855-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 US disclosed
US-8143258-B2 Benzothiazole compounds useful for Raf inhibition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-27 US disclosed
EP-2358689-A1 Benzothiazole derivatives as anticancer agents Takeda Pharmaceutical Company Limited (JP) 2011-08-24 EP disclosed
US-20100216810-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 US disclosed
WO-2010064722-A1 BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214855-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 ALDH1A1 1236/4885AURKA 869/4885AURKB 770/4885
US-20100216810-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 ALDH1A1 1236/4885AURKA 869/4885AURKB 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.